EPS for Vertex Pharmaceuticals Incorporated (VRTX) Expected At $0.05

July 18, 2017 - By Henry Gaston

 EPS for Vertex Pharmaceuticals Incorporated (VRTX) Expected At $0.05
Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.22, from 1.1 in 2016Q3. It is negative, as 48 investors sold Vertex Pharmaceuticals Incorporated shares while 165 reduced holdings. 46 funds opened positions while 141 raised stakes. 232.42 million shares or 0.81% less from 234.32 million shares in 2016Q3 were reported.
Nationwide Fund Advisors has 221,356 shares. Everpoint Asset Ltd Liability Corp stated it has 1% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Louisiana State Employees Retirement has 0.06% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Pinnacle Associate Ltd holds 0.01% or 3,700 shares. Lazard Asset Mngmt Limited Liability Company invested 0.12% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Riverhead Mgmt Lc has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ftb Advsrs Inc holds 293 shares. Endurance Wealth Management Inc holds 0.08% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 5,850 shares. Amer And Mgmt Co reported 0.23% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Fincl Bank Of Montreal Can holds 148,580 shares. Carlson Capital Lp, a Texas-based fund reported 577,656 shares. Symphony Asset Mgmt Lc holds 0.05% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 6,276 shares. Swiss Bank & Trust has 0.08% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 689,809 shares. Piedmont Inv Limited Co invested in 0% or 51,763 shares. Exane Derivatives holds 1,521 shares or 0% of its portfolio.

Since February 1, 2017, it had 0 insider buys, and 30 insider sales for $68.81 million activity. Shares for $1.09M were sold by Chodakewitz Jeffrey. 30,500 shares valued at $3.81 million were sold by Sachdev Amit on Thursday, June 1. Arbuckle Stuart A sold $335,175 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, February 13. ALTSHULER DAVID sold $561,415 worth of stock or 6,403 shares. On Monday, May 15 the insider Silva Paul M sold $31,067. 1,176 shares were sold by Bhatia Sangeeta N., worth $151,045 on Thursday, June 1.

Investors wait Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report on July, 26. its quarterly earnings Wall Street analysts expect $0.05 earnings per share, up $0.06 or 600.00 % from last year’s $-0.01 same quarter earnings. This translates into $12.46M profit for VRTX giving the stock a 646.05 P/E. This is assuming the current $0.05 EPS is accurate. Vertex Pharmaceuticals Incorporated’s Wall Street analysts see -61.54 % negative EPS growth, taking into account the $0.13 EPS reproted in the previous quarter, The stock decreased 1.36% or $1.78 during the last trading session, reaching $129.21. About 1.14 million shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since July 18, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 19 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Vertex Pharmaceuticals had 43 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, March 1 by Citigroup. The company was downgraded on Thursday, April 28 by Goldman Sachs. On Thursday, February 4 the stock rating was maintained by Argus Research with “Buy”. The firm has “Perform” rating given on Thursday, December 15 by Oppenheimer. Jefferies maintained the stock with “Buy” rating in Friday, June 9 report. The firm has “Buy” rating by Oppenheimer given on Sunday, July 9. H.C. Wainwright upgraded it to “Buy” rating and $155 target in Friday, October 30 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Hold” rating by Cowen & Co on Wednesday, July 5. The stock has “Buy” rating by Jefferies on Wednesday, October 5. H.C. Wainwright downgraded the stock to “Neutral” rating in Monday, October 24 report.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has market cap of $32.20 billion. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications. It has a 182.48 P/E ratio. The Company’s marketed medicines are ORKAMBI and KALYDECO.

More news for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were recently published by: Benzinga.com, which released: “2 Reasons Vertex Pharmaceuticals Just Got Upgraded” on June 23, 2017. Streetinsider.com‘s article titled: “Vertex Pharma (VRTX) Reports Reimbursement Agreement in Italy for ORKAMBI …” and published on July 13, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.